SI2004641T1 - HIV inhibirajoči 5-(hidroksimetilen in aminometilen) substituirani pirimidini - Google Patents

HIV inhibirajoči 5-(hidroksimetilen in aminometilen) substituirani pirimidini

Info

Publication number
SI2004641T1
SI2004641T1 SI200730458T SI200730458T SI2004641T1 SI 2004641 T1 SI2004641 T1 SI 2004641T1 SI 200730458 T SI200730458 T SI 200730458T SI 200730458 T SI200730458 T SI 200730458T SI 2004641 T1 SI2004641 T1 SI 2004641T1
Authority
SI
Slovenia
Prior art keywords
aminomethylene
hydroxymethylene
substituted pyrimidines
hiv inhibiting
hiv
Prior art date
Application number
SI200730458T
Other languages
English (en)
Inventor
Jerome Emile Georges Guillemont
Celine Isabelle Mordant
Benoit Antoine Schmitt
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of SI2004641T1 publication Critical patent/SI2004641T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
SI200730458T 2006-03-30 2007-03-30 HIV inhibirajoči 5-(hidroksimetilen in aminometilen) substituirani pirimidini SI2004641T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06112045 2006-03-30
PCT/EP2007/053113 WO2007113256A1 (en) 2006-03-30 2007-03-30 Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
EP07727585A EP2004641B1 (en) 2006-03-30 2007-03-30 Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines

Publications (1)

Publication Number Publication Date
SI2004641T1 true SI2004641T1 (sl) 2011-02-28

Family

ID=36808784

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200730458T SI2004641T1 (sl) 2006-03-30 2007-03-30 HIV inhibirajoči 5-(hidroksimetilen in aminometilen) substituirani pirimidini

Country Status (18)

Country Link
US (1) US8163745B2 (sl)
EP (1) EP2004641B1 (sl)
JP (1) JP5070278B2 (sl)
KR (1) KR20080104040A (sl)
CN (1) CN101410394B (sl)
AT (1) ATE482953T1 (sl)
AU (1) AU2007233739B2 (sl)
BR (1) BRPI0709266B8 (sl)
CA (1) CA2645959C (sl)
DE (1) DE602007009508D1 (sl)
DK (1) DK2004641T3 (sl)
ES (1) ES2353725T3 (sl)
HR (1) HRP20100696T1 (sl)
IL (1) IL193725A (sl)
MX (1) MX2008012577A (sl)
RU (1) RU2452737C2 (sl)
SI (1) SI2004641T1 (sl)
WO (1) WO2007113256A1 (sl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010051A (es) * 2005-02-18 2007-09-21 Tibotec Pharm Ltd Derivados de oxido de 2-(4-cianofenilamino)pirimidina que inhiben el virus de inmunodeficiencia humana.
DK2114901T3 (da) * 2006-12-29 2014-06-30 Janssen R & D Ireland Hiv-inhiberende 6-substituerede pyrimidiner
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP3210609A1 (en) 2008-05-21 2017-08-30 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2760794C (en) 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
KR20130099040A (ko) 2010-08-10 2013-09-05 셀진 아빌로믹스 리서치, 인코포레이티드 Btk 억제제의 베실레이트 염
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
BR112013027734A2 (pt) 2011-05-04 2017-08-08 Ariad Pharma Inc compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica
CN102260215A (zh) * 2011-05-13 2011-11-30 复旦大学 一种二芳基嘧啶类衍生物及其制备方法和用途
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
RS57901B1 (sr) 2012-03-15 2019-01-31 Celgene Car Llc Soli inhibitora kinaze receptora epidermalnog faktora rasta
EP2825041B1 (en) 2012-03-15 2021-04-21 Celgene CAR LLC Solid forms of an epidermal growth factor receptor kinase inhibitor
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Egfr発動性がんの細胞増殖阻害用化合物
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
PE20151274A1 (es) 2013-02-08 2015-09-12 Celgene Avilomics Res Inc Inhibidores de erk y sus usos
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CN103483272B (zh) * 2013-09-29 2015-10-21 山东大学 间二芳烃-多取代嘧啶类衍生物及其制备方法与应用
RU2547844C1 (ru) * 2013-10-29 2015-04-10 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук Способ получения 5-(гет)арил-4-(2-тиенил)-2-(тио)морфолилпиримидина
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
ES2741785T3 (es) 2014-08-13 2020-02-12 Celgene Car Llc Formas y composiciones de un inhibidor de ERK

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
HUP9900730A3 (en) 1995-11-23 2001-04-28 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
DE69905306T2 (de) * 1998-03-27 2003-11-27 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
NZ511116A (en) 1998-11-10 2003-08-29 Janssen Pharmaceutica Nv HIV replication inhibiting pyrimidines
WO2001085700A2 (en) * 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
DE602004021558D1 (de) * 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
PL227577B1 (pl) * 2003-02-07 2017-12-29 Janssen Pharmaceutica Nv Zastosowanie pochodnych pirymidyny do wytwarzania leku do zapobiegania zakażeniu wirusem HIV oraz kompozycja farmaceutyczna
MX2007003798A (es) * 2004-09-30 2007-04-23 Tibotec Pharm Ltd Pirimidinas 5-sustituidas con carbociclos o heterociclos inhibidoras del vih.

Also Published As

Publication number Publication date
RU2452737C2 (ru) 2012-06-10
HRP20100696T1 (hr) 2011-01-31
CN101410394A (zh) 2009-04-15
CN101410394B (zh) 2012-02-08
DK2004641T3 (da) 2011-01-24
MX2008012577A (es) 2008-10-10
WO2007113256A1 (en) 2007-10-11
CA2645959C (en) 2016-05-17
BRPI0709266A2 (pt) 2011-06-28
ATE482953T1 (de) 2010-10-15
AU2007233739A1 (en) 2007-10-11
KR20080104040A (ko) 2008-11-28
IL193725A0 (en) 2009-05-04
JP2009531395A (ja) 2009-09-03
US20100234375A1 (en) 2010-09-16
IL193725A (en) 2014-11-30
ES2353725T3 (es) 2011-03-04
BRPI0709266B8 (pt) 2021-05-25
AU2007233739B2 (en) 2013-01-17
JP5070278B2 (ja) 2012-11-07
DE602007009508D1 (de) 2010-11-11
CA2645959A1 (en) 2007-10-11
RU2008143018A (ru) 2010-05-10
BRPI0709266B1 (pt) 2020-09-29
EP2004641A1 (en) 2008-12-24
US8163745B2 (en) 2012-04-24
EP2004641B1 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
IL193725A0 (en) Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
MX2008012576A (es) Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2008031556A3 (en) 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
GEP20125701B (en) Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
MY148634A (en) Pyridazinone derivatives
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
HK1128471A1 (en) Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2008089105A3 (en) Antiviral nucleoside analogs
WO2007044565A3 (en) Composition and synthesis of new reagents for inhibition of hiv replication
MX2010004576A (es) Derivados de pirimidina novedosos.
MXPA05008368A (es) 1,2,4-triazinas inhibidoras del virus de inmunodeficiencia humana.
WO2007014352A3 (en) Antiviral phosphonate conjugates for inhibition of hiv
WO2007065595A3 (en) Xanthine derivatives, processes for preparing them and their uses
UA93599C2 (en) powder valgancyclovir preparation
MX2009008495A (es) Novedosos analogos de nucleosidos para el tratamiento de infecciones virales.
WO2009013545A3 (en) Chemical compounds
WO2006097617A3 (fr) Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
MX2009009952A (es) Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2, 2-difenilhexanamida.
EP2131849A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER
TW200621260A (en) Selected fused heterocyclics and uses thereof
HK1135329A1 (en) Stable aqueous g-csf formulations